المؤلفون: Pigeaud, Karina E., Rietveld, Melanie L., Witvliet, Aster F., Hogervorst, Jolanda M.A., Zhang, Chen, Forouzanfar, Tim, Bravenboer, Nathalie, Schoenmaker, Ton, de Vries, Teun J.

المصدر: Pigeaud , K E , Rietveld , M L , Witvliet , A F , Hogervorst , J M A , Zhang , C , Forouzanfar , T , Bravenboer , N , Schoenmaker , T & de Vries , T J 2023 , ' The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts ' , International Journal of Molecular Sciences , vol. 24 , no. 8 , 7574 . https://doi.org/10.3390/ijms24087574Test

مصطلحات موضوعية: bone balance, osteoclastogenesis, osteogenesis, periodontal ligament fibroblast, romosozumab, sclerostin

العلاقة: https://research.vu.nl/en/publications/8c5e9ff3-aa2b-450c-a1f4-c7203b60005fTest

الإتاحة: https://doi.org/10.3390/ijms24087574Test
https://research.vu.nl/en/publications/8c5e9ff3-aa2b-450c-a1f4-c7203b60005fTest
https://hdl.handle.net/1871.1/8c5e9ff3-aa2b-450c-a1f4-c7203b60005fTest
http://www.scopus.com/inward/record.url?scp=85158004624&partnerID=8YFLogxKTest
http://www.scopus.com/inward/citedby.url?scp=85158004624&partnerID=8YFLogxKTest

المؤلفون: Pigeaud, Karina E., Rietveld, Melanie L., Witvliet, Aster F., Hogervorst, Jolanda M.A., Zhang, Chen, Forouzanfar, Tim, Bravenboer, Nathalie, Schoenmaker, Ton, de Vries, Teun J.

المصدر: Pigeaud , K E , Rietveld , M L , Witvliet , A F , Hogervorst , J M A , Zhang , C , Forouzanfar , T , Bravenboer , N , Schoenmaker , T & de Vries , T J 2023 , ' The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts ' , International Journal of Molecular Sciences , vol. 24 , no. 8 , 7574 . https://doi.org/10.3390/ijms24087574Test

مصطلحات موضوعية: bone balance, osteoclastogenesis, osteogenesis, periodontal ligament fibroblast, romosozumab, sclerostin

العلاقة: https://research.vu.nl/en/publications/8c5e9ff3-aa2b-450c-a1f4-c7203b60005fTest

الإتاحة: https://doi.org/10.3390/ijms24087574Test
https://research.vu.nl/en/publications/8c5e9ff3-aa2b-450c-a1f4-c7203b60005fTest
https://hdl.handle.net/1871.1/8c5e9ff3-aa2b-450c-a1f4-c7203b60005fTest
http://www.scopus.com/inward/record.url?scp=85158004624&partnerID=8YFLogxKTest
http://www.scopus.com/inward/citedby.url?scp=85158004624&partnerID=8YFLogxKTest

المؤلفون: Brent, Mikkel Bo, Brüel, Annemarie, Thomsen, Jesper Skovhus

المصدر: Brent , M B , Brüel , A & Thomsen , J S 2022 , ' Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats ' , Bone , vol. 160 , 116417 . https://doi.org/10.1016/j.bone.2022.116417Test

مصطلحات موضوعية: Abaloparatide, Bone loss, DXA, Osteoporosis, Romosozumab, Scl-Ab

وصف الملف: application/pdf

العلاقة: https://pure.au.dk/portal/en/publications/63bcc30f-e9c3-4170-b20c-3110033febbbTest

الإتاحة: https://doi.org/10.1016/j.bone.2022.116417Test
https://pure.au.dk/portal/en/publications/63bcc30f-e9c3-4170-b20c-3110033febbbTest
https://pure.au.dk/ws/files/335428103/Anti_sclerostin_antibodies_and_abaloparatide_have_additive_effects_when_used_as_a_countermeasure_against_disuse_osteopenia_in_female_rats.pdfTest
http://www.scopus.com/inward/record.url?scp=85128178151&partnerID=8YFLogxKTest

المؤلفون: Cosman, Felicia, Kendler, David L., Langdahl, Bente L., Leder, Benjamin Z., Lewiecki, E. Michael, Miyauchi, Akimitsu, Rojeski, Maria, McDermott, Michele, Oates, Mary K., Milmont, Cassandra E., Libanati, Cesar, Ferrari, Serge

المصدر: Cosman , F , Kendler , D L , Langdahl , B L , Leder , B Z , Lewiecki , E M , Miyauchi , A , Rojeski , M , McDermott , M , Oates , M K , Milmont , C E , Libanati , C & Ferrari , S 2022 , ' Romosozumab and antiresorptive treatment : the importance of treatment sequence ' , Osteoporosis International , vol. 33 , no. 6 , pp. 1243-1256 . https://doi.org/10.1007/s00198-021-06174-0Test

مصطلحات موضوعية: Anabolic, Antiresorptive, Romosozumab, Teriparatide, Treatment sequence, Bone Density, Bone Density Conservation Agents/pharmacology, Humans, Antibodies, Monoclonal, Teriparatide/pharmacology, Osteoporosis, Postmenopausal/drug therapy, Alendronate/pharmacology, Denosumab/pharmacology, Female

وصف الملف: application/pdf

العلاقة: https://pure.au.dk/portal/da/publicationsTest/romosozumab-and-antiresorptive-treatment(fb04d75c-1cfe-42a4-9117-303a3658e1ad).html

الإتاحة: https://doi.org/10.1007/s00198-021-06174-0Test
https://pure.au.dk/portal/da/publicationsTest/romosozumab-and-antiresorptive-treatment(fb04d75c-1cfe-42a4-9117-303a3658e1ad).html
https://pure.au.dk/ws/files/347114366/s00198-021-06174-0.pdfTest
http://www.scopus.com/inward/record.url?scp=85124754008&partnerID=8YFLogxKTest

المؤلفون: Miller, Paul D., Adachi, Jonathan D., Albergaria, Ben Hur, Cheung, Angela M., Chines, Arkadi A., Gielen, Evelien, Langdahl, Bente L., Miyauchi, Akimitsu, Oates, Mary, Reid, Ian R., Santiago, Norma Ruiz, Vanderkelen, Mark, Wang, Zhenxun, Yu, Zhigang

المصدر: Miller , P D , Adachi , J D , Albergaria , B H , Cheung , A M , Chines , A A , Gielen , E , Langdahl , B L , Miyauchi , A , Oates , M , Reid , I R , Santiago , N R , Vanderkelen , M , Wang , Z & Yu , Z 2022 , ' Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease ' , Journal of Bone and Mineral Research , vol. 37 , no. 8 , pp. 1437-1445 . ....

مصطلحات موضوعية: ANABOLICS, CHRONIC KIDNEY DISEASE, MENOPAUSE, OSTEOPOROSIS, ROMOSOZUMAB

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1002/jbmr.4563Test
https://pure.au.dk/portal/da/publications/efficacy-and-safety-ofTest-romosozumab-among-postmenopausal-women-with-osteoporosis-and-mildtomoderate-chronic-kidney-disease(6e1159b5-a9aa-415a-afe4-1b1285f1835b).html
https://pure.au.dk/ws/files/346314492/Efficacy_and_Safety_of_Romosozumab_Among_Postmenopausal_Women_With_Osteoporosis_and_Mild-to-Moderate_Chronic_Kidney_Disease.pdfTest
http://www.scopus.com/inward/record.url?scp=85130218394&partnerID=8YFLogxKTest

المؤلفون: Brent, Mikkel Bo, Brüel, Annemarie, Thomsen, Jesper Skovhus

المصدر: Brent , M B , Brüel , A & Thomsen , J S 2022 , ' Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats ' , Bone , vol. 160 , 116417 . https://doi.org/10.1016/j.bone.2022.116417Test

مصطلحات موضوعية: Abaloparatide, Bone loss, DXA, Osteoporosis, Romosozumab, Scl-Ab, Parathyroid Hormone-Related Protein/pharmacology, Bone Density, Rats, Wistar, Humans, Bone Diseases, Metabolic/prevention & control, Animals, Female

وصف الملف: application/pdf

العلاقة: https://vbn.aau.dk/da/publications/ac2b0a60-7b1e-4336-9297-6e7979dde73bTest

الإتاحة: https://doi.org/10.1016/j.bone.2022.116417Test
https://vbn.aau.dk/da/publications/ac2b0a60-7b1e-4336-9297-6e7979dde73bTest
https://vbn.aau.dk/ws/files/470045043/Brent_Br_el_Thomsen_2022_Anti_sclerostin_antibodies_and_abaloparatide_have_additive_effects_when_used_as_a_countermeasure_against_disuse_osteopenia_in_female_rats.pdfTest
http://www.scopus.com/inward/record.url?scp=85128178151&partnerID=8YFLogxKTest

المؤلفون: McClung, Michael R., Bolognese, Michael A., Brown, Jacques P., Reginster, Jean Yves, Langdahl, Bente L., Shi, Yifei, Timoshanko, Jen, Libanati, Cesar, Chines, Arkadi, Oates, Mary K.

المصدر: McClung , M R , Bolognese , M A , Brown , J P , Reginster , J Y , Langdahl , B L , Shi , Y , Timoshanko , J , Libanati , C , Chines , A & Oates , M K 2021 , ' Skeletal responses to romosozumab after 12 months of denosumab ' , JBMR Plus , vol. 5 , no. 7 , e10512 . https://doi.org/10.1002/jbm4.10512Test

مصطلحات موضوعية: ANABOLIC, ANTIRESORPTIVE, DENOSUMAB, ROMOSOZUMAB, TREATMENT SEQUENCE

الإتاحة: https://doi.org/10.1002/jbm4.10512Test
https://pure.au.dk/portal/da/publications/skeletal-responses-toTest-romosozumab-after-12-months-of-denosumab(8a0ae335-220b-47cd-bd6c-c450d8378287).html
http://www.scopus.com/inward/record.url?scp=85107026945&partnerID=8YFLogxKTest

المؤلفون: McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J. Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., Grauer, A.

المصدر: McClung , M R , Bolognese , M A , Brown , J P , Reginster , J Y , Langdahl , B L , Maddox , J , Shi , Y , Rojeski , M , Meisner , P D & Grauer , A 2020 , ' A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab ' , Osteoporosis International , vol. 31 , no. 11 , pp. 2231-2241 . https://doi.org/10.1007/s00198-020-05502-0Test

مصطلحات موضوعية: Antiresorptive, Bone mineral density, Follow-on regimen, Osteoporosis, Romosozumab

وصف الملف: application/pdf

العلاقة: https://pure.au.dk/portal/en/publications/cf3723a0-c6bb-49c6-84bd-78cffeed339dTest

الإتاحة: https://doi.org/10.1007/s00198-020-05502-0Test
https://pure.au.dk/portal/en/publications/cf3723a0-c6bb-49c6-84bd-78cffeed339dTest
https://pure.au.dk/ws/files/220347067/McClung2020_Article_ASingleDoseOfZoledronatePreser.pdfTest
http://www.scopus.com/inward/record.url?scp=85087569887&partnerID=8YFLogxKTest

المؤلفون: Cosman, Felicia, Lewiecki, E. Michael, Ebeling, Peter R., Hesse, Eric, Napoli, Nicola, Matsumoto, Toshio, Crittenden, Daria B., Rojeski, Maria, Yang, Wenjing, Libanati, Cesar, Ferrari, Serge

المصدر: Cosman , F , Lewiecki , E M , Ebeling , P R , Hesse , E , Napoli , N , Matsumoto , T , Crittenden , D B , Rojeski , M , Yang , W , Libanati , C & Ferrari , S 2020 , ' T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial ' , Journal of Bone and Mineral Research , vol. 35 , no. 7 , pp. 1333-1342 . https://doi.org/10.1002/jbmr.3996Test

مصطلحات موضوعية: ALENDRONATE, BONE MINERAL DENSITY, POSTMENOPAUSAL OSTEOPOROSIS, ROMOSOZUMAB, T-SCORE

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1002/jbmr.3996Test
https://research.monash.edu/en/publications/ef4f3b26-9f36-440c-9f4a-08e38d98fe88Test
https://researchmgt.monash.edu/ws/files/322071329/311624587_oa.pdfTest
http://www.scopus.com/inward/record.url?scp=85085560614&partnerID=8YFLogxKTest

المؤلفون: Adami, Giovanni, Saag, Kenneth G., Chapurlat, Roland D., Guanabens, Nuria, Haugeberg, Glenn, Lems, Willem F., Matijevic, Radmila, Peel, Nicola, Poddubnyy, Denis, Geusens, Piet

المصدر: Adami , G , Saag , K G , Chapurlat , R D , Guanabens , N , Haugeberg , G , Lems , W F , Matijevic , R , Peel , N , Poddubnyy , D & Geusens , P 2019 , ' Balancing benefits and risks in the era of biologics ' , Therapeutic Advances in Musculoskeletal Disease , vol. 11 , ARTN 1759720X19883973 . https://doi.org/10.1177/1759720X19883973Test

مصطلحات موضوعية: benefit-risk ratio, biologics, denosumab, romosozumab, POSTMENOPAUSAL WOMEN, RHEUMATOID-ARTHRITIS, CERTOLIZUMAB PEGOL, PREVENTION, INFLIXIMAB, FRACTURES, DISEASES, SAFETY

الإتاحة: https://doi.org/10.1177/1759720X19883973Test
https://cris.maastrichtuniversity.nl/en/publications/a27a76f2-d675-4c70-8609-973c227600b8Test